SCHEMBL24196243

SCHEMBL24196243

CCc1cccc(OCC2CCCCC2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TLR4 O00206 1/20 0.50
TLR2 O60603 1/20 0.50
SLC2A1 P11166 1/20 0.49
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
PARP15 Q460N3 2/20 0.47
PARP10 Q53GL7 2/20 0.47
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47
CCNA1 P78396 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
GRM2 Q14416 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.45
CETP P11597 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11941578 0.98 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2TLR4TLR2
SCHEMBL24780621 0.95 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2TLR4TLR2
SCHEMBL11942141 0.92 ALDH1A1 (0.51) KDM4EALDH1A1SMN1; SMN2TLR4TLR2
SCHEMBL3972767 0.88 TLR4 (0.48) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL3970976 0.88 TLR4 (0.48) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL3969096 0.86 TLR4 (0.46) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL3967742 0.85 SLC2A1 (0.48) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL4568750 0.85 SLC2A1 (0.48) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL4568833 0.85 SLC2A1 (0.48) TLR4TLR2SLC2A1MAOAMAOB
SCHEMBL13462885 0.85 KDM4E (0.56) KDM4EALDH1A1SMN1; SMN2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
WO-2022008475-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 KDM4E 1643/4885ALDH1A1 995/4885SMN1; SMN2 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.